CytoDyn Inc.

Equities

CYDY

US23283M1018

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 02:05:35 2024-04-29 pm EDT			5-day change	1st Jan Change
0.14 ^USD	-2.10%		-6.73%	-28.21%

Apr. 15	CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI
Mar. 05	Transcript : CytoDyn Inc. - Special Call

CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022

January 09, 2023 at 05:29 pm EST

CytoDyn Inc. reported earnings results for the second quarter and six months ended November 30, 2022. For the second quarter, the company reported net loss was USD 26.5 million compared to USD 40.08 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.06 a year ago.
For the six months, net loss was USD 47.49 million compared to USD 85.41 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.13 a year ago.

Latest news about CytoDyn Inc.

CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 15	CI
Transcript : CytoDyn Inc. - Special Call	Mar. 05
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	Feb. 01	CI
Cytodyn Inc. Announces CFO Changes	Jan. 29	CI
CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEO	Jan. 29	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 16	CI
CytoDyn Inc. announced a financing transaction	Dec. 28	CI
Transcript : CytoDyn Inc. - Special Call	Dec. 14
CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEO	Nov. 21	CI
CytoDyn Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-23	CI
CytoDyn Inc. Reports Earnings Results for the Full Year Ended May 31, 2023	23-09-14	CI
Transcript : CytoDyn Inc. - Special Call	23-07-24
CytoDyn Inc. Announces CEO Changes	23-07-11	CI
CytoDyn Inc. Announces Executive Changes	23-07-11	CI
CytoDyn Inc. Announces Executive Changes	23-05-24	CI
Transcript : CytoDyn Inc. - Special Call	23-04-11
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	23-04-10	CI
CytoDyn Inc. announced that it has received $4.899 million in funding	23-03-02	CI
CytoDyn Inc. announced that it expects to receive $7.866 million in funding	23-01-12	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	23-01-09	CI
Transcript : CytoDyn Inc. - Special Call	22-12-29
MarketScreener's World Press Review: December 21, 2022	22-12-21
CytoDyn Inc. Announces Resignation of Scott A. Kelly, Chief Medical Officer	22-12-19	CI
Transcript : CytoDyn Inc. - Special Call	22-12-07
Nitya G. Ray Resigns as Chief Technology Officer of CytoDyn Inc	22-11-25	CI

Chart CytoDyn Inc.

Duration

Period

More charts

Company Profile

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTODYN INC.	-28.21%	142M
VERTEX PHARMACEUTICALS INCORPORATED	-2.51%	103B
REGENERON PHARMACEUTICALS, INC.	+1.79%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.54%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-12.61%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.35%	13.68B
SAREPTA THERAPEUTICS, INC.	+34.45%	12.17B

Bio Therapeutic Drugs